This publication does not concern the award of a public contract within the meaning of the Procurement Coordination Directive (2014/24/EU) or antitrust law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text (section IV.1.1) is due to the specifications of the announcement form. This and the use of the medium “TED” does not involve any submission under procurement regulations whose validity is not mandatory by law or procurement regulations. It is a framework agreement with an option to join, which relates to various active substances.

In the contract, drugs containing the active substance bexarotene are drugs.

In the contract, drugs containing the active substance iloprost are drugs.

In terms of the contract, drugs that contain the active substance melatonin in a prescription, oral, retardated dosage form are products.

The subject of the contract are medicinal products that contain the active ingredient mepolizumab in the potency of 100mg and in the dosage form pre-filled syringe.

The subject of the contract are medicinal products containing the active ingredient nilotinib.

In the contract, drugs containing the active substance peginterferon beta-1a are medicines.

The subject of the contract are medicinal products that contain the active ingredient combination piribedil.

In the contract, drugs that contain the active substance rilpivirine in the dosage form are film-coated tablets.

The subject of the contract are medicinal products that contain the active ingredient salmeterol in the dosage form metered-dose inhaler.

In the contract, drugs containing the active substance sirolimus are drugs.

In the contract, drugs containing the active substance tafamidis are drugs.

In terms of the contract, drugs that contain the active substance buserelin in the dosage form implant are implant.

The subject of the contract are medicinal products that contain the active ingredient combination tafluprost and timolol.

The subject of the contract are medicinal products containing the active ingredient teriflunomide.

The subject of the contract are medicinal products that contain the active ingredient teriparatide (Forsteo®) or are interchangeable with it according to the rules of substitution. The criteria for substitution are defined in the framework agreement on the supply of medicinal products in accordance with Section 129 (2) SGB V in the currently valid version.

The subject of the contract are medicinal products that contain the active ingredient teriparatide (Livogiva®) or are interchangeable with it in accordance with the rules of substitution. The criteria for substitution are defined in the framework agreement on the supply of medicinal products in accordance with Section 129 (2) SGB V in the currently valid version.

The subject of the contract are medicinal products that contain the active ingredient teriparatide (Movymia®_Terrosa® or are interchangeable with them according to the rules of substitution. The criteria for substitution are defined in the framework agreement on the supply of medicinal products in accordance with Section 129 (2) SGB V in the currently valid version.

In the contract, drugs containing the active substance caspofungin are medicines.

The subject of the contract are medicinal products that contain the active ingredient cefadroxil in the dosage form of a tablet.

In the contract, drugs containing the active substance dasatinib are medicines.

Medicinal products containing the active substance dasatinib in a patent-free indication are the contractual objective.

In the contract, drugs containing the active substance dexamethasone in the dosage form ampoule are.

The subject of the contract are medicinal products that contain the active ingredient fluorouracil in the dosage form cream.

The subject of the contract are medicinal products containing the active ingredient combination fluticasone furoate and vilanterol.